# Study of Oral MRT-2359 in Selected Cancer Patients

> **NCT05546268** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Monte Rosa Therapeutics, Inc** · enrollment: 174 (estimated)

## Conditions studied

- NSCLC
- SCLC
- High Grade Neuroendocrine Cancer
- DLBCL
- L-MYC and N-MYC Amplified Solid Tumors
- NSCLC With High or Low L-MYC or N-MYC Expression
- HR-positive, HER2-negative Breast Cancer
- Prostate Cancer

## Interventions

- **DRUG:** Oral MRT-2359
- **DRUG:** Oral MRT-2359
- **DRUG:** Oral MRT-2359
- **DRUG:** Oral MRT-2359
- **DRUG:** Oral MRT-2359
- **DRUG:** Oral MRT-2359

## Key facts

- **NCT ID:** NCT05546268
- **Lead sponsor:** Monte Rosa Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-12
- **Primary completion:** 2026-05
- **Final completion:** 2027-11
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546268, "Study of Oral MRT-2359 in Selected Cancer Patients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05546268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*